NASDAQ:RAPP Rapport Therapeutics Q3 2024 Earnings Report $14.60 -0.78 (-5.07%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$14.60 0.00 (-0.03%) As of 07/11/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Rapport Therapeutics EPS ResultsActual EPS-$0.50Consensus EPS -$0.57Beat/MissBeat by +$0.07One Year Ago EPSN/ARapport Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARapport Therapeutics Announcement DetailsQuarterQ3 2024Date11/7/2024TimeBefore Market OpensConference Call DateThursday, November 7, 2024Conference Call Time7:00AM ETUpcoming EarningsRapport Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Rapport Therapeutics Earnings HeadlinesRapport Therapeutics stock rating reiterated as Buy by TD CowenJuly 2, 2025 | uk.investing.comStifel reiterates buy rating for Rapport Therapeutics stockJune 5, 2025 | uk.investing.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year. | Weiss Ratings (Ad)Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical PipelineJune 4, 2025 | nasdaq.comRapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate UpdatesJune 2, 2025 | globenewswire.comRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare ConferenceMay 27, 2025 | globenewswire.comSee More Rapport Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rapport Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rapport Therapeutics and other key companies, straight to your email. Email Address About Rapport TherapeuticsRapport Therapeutics (NASDAQ:RAPP) is a clinical-stage biotechnology company focused on the discovery and development of next-generation immuno-oncology therapies. Leveraging its proprietary ARCas (Allele-Rich Cell Assay Screening) platform, the company aims to identify and optimize fully human monoclonal antibodies and multispecific formats that selectively modulate both innate and adaptive immune pathways. Rapport’s pipeline targets novel checkpoints and costimulatory receptors to enhance anti-tumor responses while minimizing off-target toxicity. The ARCas discovery engine integrates high-throughput single-cell screening with CRISPR-mediated target validation, enabling rapid identification of lead antibody candidates. In 2022, Rapport expanded its platform capabilities through the acquisition of Adagene’s Integrum™ Fc-engineering technology, adding tailored Fc modifications and multispecific scaffolds to its repertoire. The combined platforms support a growing preclinical portfolio that includes bispecific T-cell engagers, agonists for co-stimulatory receptors, and innate immune modulators. Founded in 2017 as Cullinan Oncology, the company rebranded to Rapport Therapeutics following its strategic platform merger and Nasdaq listing under the ticker RAPP. Headquartered in San Francisco with additional facilities in New York, Rapport is backed by leading life-science investors and maintains collaborations with academic cancer centers and contract research organizations. The senior management team comprises seasoned executives and scientists with extensive experience in biologics development, translational immunology, and regulatory strategy. Rapport’s research and development efforts are primarily centered in North America, with ongoing partnerships and research alliances in Europe and the Asia-Pacific region. The company is advancing its lead candidates toward Investigational New Drug (IND) filings and anticipates initiating first-in-human studies to evaluate safety, pharmacokinetics, and early signals of clinical activity in solid tumors and hematological malignancies.Written by Jeffrey Neal JohnsonView Rapport Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
